Börse:
21,963€
7,47%
Echtzeit-Aktienkurs Aerie Pharmaceuticals
Bid:
21,645€
Ask:
22,280€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 998,83 Mio. EUR (45,48 Mio. x 21,963€) | |
| Website: | - | |
| Sektor: | Medizin / Biotech | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2016 | 2017 | 2018 | |
|---|---|---|---|
| KUV | - | - | 41,31 |
| KGV | - | - | - |
| Div. Rend. | - | - | - |
Echtzeit-Chart der Aerie Pharmaceuticals Aktie
Börsenkurse Aerie Pharmaceuticals
| Euro Indikation | 21,860€ | 0 | 22,085€ | 0 | 21,973€ | 3,13% |
| Börse Stuttgart | 21,645€ | 0 | 22,280€ | 0 | 21,963€ | 7,47% |
| Dollar Indikation | 24,041$ | 0 | 24,643$ | 0 | 24,342$ | 8,19% |
| Lang & Schwarz | 21,860€ | 592 | 22,035€ | 592 | 21,948€ | 8,44% |
| Tradegate | 21,740€ | 184 | 22,185€ | 180 | 21,963€ | 8,52% |
Fundamentaldaten der Aerie Pharmaceuticals Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 24,18 Mio. | -232,57 Mio. | -232,57 Mio. | -5,58 | 0,00% | - | 41,31 |
| 2017 | 0,00 Mio. | -146,86 Mio. | -145,11 Mio. | -4,11 | 0,00% | - | - |
| 2016 | 0,00 Mio. | -98,87 Mio. | -99,06 Mio. | -3,40 | 0,00% | - | - |
Profil der Aerie Pharmaceuticals Aktie
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company's product candidates are Rhopressa and Roclatan. Aerie Pharmaceuticals was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem and Eric J. Toone on June 22, 2005 and is headquartered in Irvine, CA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen